Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vandetanib in advanced NSCLC
NCT00252746Phase 2Completed
- Sponsor
- Sanofi
- Start
- Dec 2004
- Primary completion
- Jan 2007
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vandetanib in non-small cell lung carcinoma (NSCLC), sponsored by Sanofi. Primary endpoint: Objective Response Rate at 24 weeks. Started Dec 2004; status: completed.
02
Drugs
vandetanib
03
Conditions
non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT00252746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00252746.